The licence from Genentech to us is well established and so is the fact we will hold multiple partners across our compound portfolio... it’s not an exclusive relationship be wary of people posting twisted words.
Our priority, as always, is to ensure that any transaction delivers the maximum value for shareholders,
the growing body of data over the coming twelve months will undoubtedly help to demonstrate the value of our drug.
Along the way, we anticipate seeing regular data read-outs,
both from our own studies in glioblastoma,
and
from the growing portfolio of collaborations and partnerships.
i don’t think we have fully heard of all the collaborations as yet
